Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: New clinical opportunities

Hang Chen, Shiyu Wang, Haiyuan Zhang, Edouard C. Nice, Canhua Huang

Research output: Contribution to journalArticleResearchpeer-review

50 Citations (Scopus)


Introduction: Nicotinamide phosphoribosyltransferase (Nampt) is the rate-limiting enzyme that catalyzes the first step in the mammalian nicotinamide adenine dinucleotide (NAD) salvage pathway. Aberrant NAD metabolism was associated with oncogenic signal transduction, suggesting the critical roles of Nampt in tumorigenesis and metastasis. Additionally, Nampt can be secreted out of the cell, and this extracellular form of Nampt (eNampt) was shown to induce inflammation and angiogenesis due to its cytokine activity, which may also be involved in carcinogenesis. Areas covered: This article reviews recent advances in the studies of Nampt in carcinogenesis, with a special highlight on Nampt inhibitors and future clinical application, including cancer diagnosis, prognosis and therapy. Expert commentary: Nampt not only maintains the balance of cellular metabolism, but also has a profound influence on multiple aspects of carcinogenesis. Therefore, elucidation of these mechanisms opens the door for future clinical applications targeting this protein. Additional studies are needed to address important questions including the relationship between extracellular Nampt and carcinogenesis.
Original languageEnglish
Pages (from-to)827-838
Number of pages12
JournalExpert Review of Anticancer Therapy
Issue number8
Publication statusPublished - 5 Jul 2016


  • Nampt
  • NAD metabolism
  • cytokine
  • carcinogenesis biomarker
  • inhibitor therapy

Cite this